Bruker (BRKR) Stock News

Bruker Corporation (NASDAQ: BRKR) has acquired biocrates life sciences ag, an Austrian leader in mass spectrometry-based quantitative metabolite and lipid analysis. biocrates specializes in metabolomics kits covering over 1,000+ metabolites from more than 40 metabolite classes, combining innovative sample preparation, metabolite identification, and data analysis. This strategic acquisition enhances Bruker's MS-based metabolomics solutions and supports its expansion into multiomics solutions, following previous acquisitions of PreOmics and Biognosys. The acquisition strengthens Bruker's position in the life sciences, biopharma R&D, and clinical research sectors by providing integrated multiomics capabilities. Financial terms of the acquisition were not disclosed.

Bruker Corporation (BRKR) has unveiled the timsUltra AIP mass spectrometer featuring the breakthrough Athena Ion Processor technology at the 73rd ASMS Conference. The new system delivers enhanced sensitivity with up to 35% more peptide and 20% more protein identifications for ultra-high sensitivity 4D-Proteomics. When combined with the Evosep Eno nLC system, it can identify over 5000 proteins at 250 pg sample size with 100 samples per day throughput, or 2000 proteins at 500 samples per day. The technology significantly advances research capabilities in single-cell proteomics, FNA tumor biopsies, immunopeptidomics, and metaproteomics, enabling detection of bacterial peptides at sub-picogram levels.

Bruker Corporation (BRKR) has unveiled the proteoElute nanoLC system and PepSep Advanced nLC columns at the 73rd ASMS Conference. The proteoElute system features ceramic valves, proteoTrap trapping columns, and TwinScape technology for predictive maintenance, designed for ultra-sensitive proteomics workflows. Key improvements include a 3x reduction in carry-over and real-time system health monitoring. The new PepSep Advanced nLC columns demonstrate approximately 20% improvements in peptide IDs and 10% improvements in protein IDs, offering sharper peaks and higher-resolution separations. The combined solution enhances robustness, sensitivity, and proteome coverage for applications like single-cell proteomics and immunopeptidomics.

Bruker Corporation (BRKR) announced its participation in the upcoming Jefferies Global Healthcare Conference in New York City. The company's senior leadership will engage in a fireside chat presentation on Wednesday, June 4th, 2025, at 5:30 PM Eastern Time. Investors can access a live audio webcast of the presentation through Bruker's Investor Relations website at https://ir.bruker.com. The presentation recording will be available in the Events & Presentations section for 30 days following the event.

Bruker Corporation (BRKR) has launched the timsOmni™ mass spectrometer, a revolutionary system that enables unprecedented protein analysis capabilities. The device combines timsTOF technology with novel Omnitrap functionality, offering high-speed, high-sensitivity protein analysis and deep sequence coverage. Key features include multimodal electron and collision-induced ion fragmentation, precise electron energy control, and collision-induced unfolding. The system is supported by OmniScape™ software, which uses machine learning for advanced protein analysis. The timsOmni is particularly valuable for analyzing proteoforms, post-translational modifications, and complex biomolecules, making it essential for disease research, biologics development, and bioprocessing quality control. Notable applications include mapping histone modifications, analyzing glycosylation, and sequencing therapeutic antibodies.

Bruker Corporation (BRKR) has unveiled the timsMetabo, a cutting-edge 4D-Metabolomics mass spectrometer at the 73rd ASMS Conference. This breakthrough system features novel TIMS Mobility Range Enhancement (MoRE) technology and delivers exceptional sensitivity and separation power for small molecule analysis. The timsMetabo enables the creation of a 'digital metabolome archive' for each sample, utilizing trapped ion mobility separation technology and time-focusing capabilities. Key innovations include the dual-stage TIMS-MX ion funnel, high-precision quadrupole, and Athena Ion Processor (AIP), allowing for improved isomer resolution and MS/MS acquisition rates up to 300 Hz. The system supports both HESI and CSI ion sources and is complemented by the new QSee quality control suite with cloud-based TwinScape software for automated performance monitoring.

Bruker Corporation (BRKR) has launched the MOVE-T, an advanced liquid dairy analyzer utilizing Fourier Transform Near-Infrared (FT-NIR) technology. The system is designed for analyzing raw milk and other liquid dairy products, featuring a wear-free quartz cell for enhanced sensitivity and transferability. The MOVE-T complies with ISO 21543 (IDF 201) standards and is specifically tailored for the dairy industry and sectors processing liquid dairy products or plant-based drinks. GOLDSTEIG Cheese Factories has already implemented the system, praising its compact design, workflow integration, and method transferability. This launch completes Bruker's portfolio of dairy FT-NIR analyzers for laboratory and process control applications.

Bruker Corporation (NASDAQ: BRKR) has announced a quarterly cash dividend payment approved by its Board of Directors. The company will distribute $0.05 per share to stockholders. The dividend will be paid on June 27, 2025, to shareholders of record as of June 16, 2025.

Bruker Corporation (BRKR) has announced a global settlement with 10x Genomics to resolve their ongoing patent disputes. The settlement includes global patent cross-license agreements between both companies and will result in the dismissal of all pending lawsuits and administrative proceedings in multiple countries, including the United States, Germany, and before the European Unified Patent Court.

According to Mark R. Munch, Ph.D., President of the Bruker Nano Group, this resolution ensures that the scientific community can continue their research using Bruker's CosMx® and GeoMx® spatial biology platforms without concerns about litigation interference, particularly in fields such as oncology and neurobiology.